Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
19 mai 2016 12h15 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma to Present the GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
18 mai 2016 17h45 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update
10 mai 2016 16h10 HE
|
Galena Biopharma, Inc.
NeuVax™ (nelipepimut-S) Phase 3, PRESENT clinical trial reaches 70th qualifying disease free survival eventPRESENT Interim safety and futility analysis expected at the end of Q2$23.4 million in net...
Galena Biopharma to Report First Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, May 10, 2016
27 avr. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Appoints Mary Ann Gray, Ph.D., to Its Board of Directors
26 avr. 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting
19 avr. 2016 09h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Phase 3 PRESENT Clinical Trial with NeuVax™ (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event
29 mars 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Corrects Error in Form 10-K
11 mars 2016 13h56 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update
10 mars 2016 16h10 HE
|
Galena Biopharma, Inc.
Two Key Milestones in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT Clinical Trial Expected in 1H, 2016Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T. SAN RAMON,...
Galena Biopharma to Present at the 28th Annual ROTH Conference
07 mars 2016 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...